Associations of Anxiety Sensitivity and Emotional Symptoms with the Subjective Effects of Alcohol, Cigarettes, and Cannabis in Adolescents
Overview
Social Sciences
Affiliations
Maladaptive emotional traits (anxiety sensitivity [AS], fear of anxiety-related sensations and consequences) and symptoms (major depressive disorder [MDD] and generalized anxiety disorder [GAD] symptoms) could play a role in altering sensitivity to the subjective effects of drugs of abuse in adolescents. Data were drawn from a longitudinal study of high school students in Los Angeles, CA, USA who completed surveys and reported past six-month use of alcohol (n=1054), cigarettes (n=297), or cannabis (n=706). At each of the four semi-annual waves during mid-adolescence (14-16years old), students reported positive and negative subjective drug effects experienced in the prior six-months. Controlling for covariates and the simultaneous covariance across the three domains of emotional dysfunction, AS was associated with more positive and negative cannabis effects (βs=0.09-0.16, ps<0.05), and MDD symptoms were associated with fewer negative cigarette effects (β=-0.13, p=0.04) and more negative cannabis effects (β=0.10, p=0.004). The acceleration of positive alcohol and cannabis effects over time was slower among adolescents with higher baseline MDD (MDD×time: β=-0.04, p=0.044) and GAD (GAD×time: β=-0.05, p=0.03) symptoms, respectively. These findings suggest that emotional dysfunction factors show differential and overlapping effects on subjective drug effects, which may vary across time. Future research should investigate emotional dysfunctions and subjective drug effects in relation to substance use across adolescence and emerging adulthood.
Guillot C, Pang R, Vilches J, Arnold M, Cajas J, Aleman A Exp Clin Psychopharmacol. 2023; 32(1):90-103.
PMID: 37358544 PMC: 10749990. DOI: 10.1037/pha0000668.
A Scoping Review of Associations Between Cannabis Use and Anxiety in Adolescents and Young Adults.
Stiles-Shields C, Archer J, Zhang J, Burnside A, Draxler J, Potthoff L Child Psychiatry Hum Dev. 2021; 54(3):639-658.
PMID: 34724134 PMC: 9310430. DOI: 10.1007/s10578-021-01280-w.
Kamboj S, Zhao H, Troebinger L, Piazza G, Cawley E, Hennessy V Int J Neuropsychopharmacol. 2021; 24(7):551-561.
PMID: 33667308 PMC: 8299821. DOI: 10.1093/ijnp/pyab009.
Li X, Hempel B, Yang H, Han X, Bi G, Gardner E Eur Neuropsychopharmacol. 2020; 43:38-51.
PMID: 33334652 PMC: 7854511. DOI: 10.1016/j.euroneuro.2020.11.019.
Bilsky S, Cloutier R, Guillot C, Bynion T, Lewis S Subst Use Misuse. 2019; 54(13):2207-2217.
PMID: 31299868 PMC: 6849207. DOI: 10.1080/10826084.2019.1638937.